Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Kadmon stock | $9.405

Learn how to easily invest in Kadmon stock.

Kadmon Holdings Inc is a biotechnology business based in the US. Kadmon shares (KDMN) are listed on the NASDAQ and all prices are listed in US Dollars. Kadmon employs 127 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Kadmon

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – KDMN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Kadmon stock price (NASDAQ: KDMN)

Use our graph to track the performance of KDMN stocks over time.

Kadmon shares at a glance

Information last updated 2021-10-24.
Latest market close$9.41
52-week range$3.15 - $9.42
50-day moving average $8.77
200-day moving average $5.28
Wall St. target price$12.10
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-0.66

Buy Kadmon shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Kadmon stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Kadmon price performance over time

Historical closes compared with the close of $9.405 from 2021-10-22

1 week (2021-10-19) 10.13%
1 month (2021-09-24) 6.51%
3 months (2021-07-26) 133.37%
6 months (2021-04-26) 132.22%
1 year (2020-10-26) 177.03%
2 years (2019-10-25) 198.57%
3 years (2018-10-26) 298.52%
5 years (2016-10-26) 50.96%

Kadmon financials

Revenue TTM $1.5 million
Gross profit TTM $6.3 million
Return on assets TTM -28.33%
Return on equity TTM -113.05%
Profit margin 0%
Book value $0.08
Market capitalisation $1.7 billion

TTM: trailing 12 months

Shorting Kadmon shares

There are currently 24.0 million Kadmon shares held short by investors – that's known as Kadmon's "short interest". This figure is 6.1% down from 25.6 million last month.

There are a few different ways that this level of interest in shorting Kadmon shares can be evaluated.

Kadmon's "short interest ratio" (SIR)

Kadmon's "short interest ratio" (SIR) is the quantity of Kadmon shares currently shorted divided by the average quantity of Kadmon shares traded daily (recently around 13.8 million). Kadmon's SIR currently stands at 1.74. In other words for every 100,000 Kadmon shares traded daily on the market, roughly 1740 shares are currently held short.

However Kadmon's short interest can also be evaluated against the total number of Kadmon shares, or, against the total number of tradable Kadmon shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Kadmon's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Kadmon shares in existence, roughly 140 shares are currently held short) or 0.1439% of the tradable shares (for every 100,000 tradable Kadmon shares, roughly 144 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Kadmon.

Find out more about how you can short Kadmon stock.

Kadmon share dividends

We're not expecting Kadmon to pay a dividend over the next 12 months.

Kadmon share price volatility

Over the last 12 months, Kadmon's shares have ranged in value from as little as $3.145 up to $9.42. A popular way to gauge a stock's volatility is its "beta".

KDMN.US volatility(beta: 1.24)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kadmon's is 1.2354. This would suggest that Kadmon's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Kadmon overview

Kadmon Holdings, Inc. , a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include Belumosudil (KD025), an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2 (ROCK2), which is in Phase II clinical trial for the treatment of chronic graft-versus-host, as well as systemic sclerosis, an autoimmune disease characterized by chronic inflammation, fibrosis, and vascular damage; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp.

Frequently asked questions

What percentage of Kadmon is owned by insiders or institutions?
Currently 0.164% of Kadmon shares are held by insiders and 100.972% by institutions.
How many people work for Kadmon?
Latest data suggests 127 work at Kadmon.
When does the fiscal year end for Kadmon?
Kadmon's fiscal year ends in December.
Where is Kadmon based?
Kadmon's address is: 450 East 29th Street, New York, NY, United States, 10016
What is Kadmon's ISIN number?
Kadmon's international securities identification number is: US48283N1063
What is Kadmon's CUSIP number?
Kadmon's Committee on Uniform Securities Identification Procedures number is: 48283N106

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site